Supernus Pharmaceuticals Cost of Goods Sold 2011-2024 | SUPN

Supernus Pharmaceuticals cost of goods sold from 2011 to 2024. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
Supernus Pharmaceuticals Annual Cost of Goods Sold
(Millions of US $)
2023 $84
2022 $87
2021 $75
2020 $52
2019 $17
2018 $15
2017 $15
2016 $12
2015 $8
2014 $6
2013 $1
2012 $
2011 $
2010 $
Supernus Pharmaceuticals Quarterly Cost of Goods Sold
(Millions of US $)
2024-06-30 $18
2024-03-31 $16
2023-12-31 $20
2023-09-30 $20
2023-06-30 $21
2023-03-31 $23
2022-12-31 $23
2022-09-30 $26
2022-06-30 $20
2022-03-31 $18
2021-12-31 $17
2021-09-30 $18
2021-06-30 $25
2021-03-31 $15
2020-12-31 $19
2020-09-30 $21
2020-06-30 $8
2020-03-31 $4
2019-12-31 $4
2019-09-30 $5
2019-06-30 $4
2019-03-31 $4
2018-12-31 $4
2018-09-30 $4
2018-06-30 $4
2018-03-31 $3
2017-12-31 $4
2017-09-30 $4
2017-06-30 $4
2017-03-31 $3
2016-12-31 $4
2016-09-30 $3
2016-06-30 $3
2016-03-31 $2
2015-12-31 $3
2015-09-30 $2
2015-06-30 $2
2015-03-31 $2
2014-12-31 $2
2014-09-30 $1
2014-06-30 $2
2014-03-31 $0
2013-12-31 $1
2013-09-30 $0
2013-06-30 $0
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.022B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.679B 6.46
Dr Reddy's Laboratories (RDY) India $12.521B 23.96
BridgeBio Pharma (BBIO) United States $4.911B 0.00
Bausch Health Cos (BHC) Canada $3.439B 2.49
Amphastar Pharmaceuticals (AMPH) United States $2.335B 14.04
Taysha Gene Therapies (TSHA) United States $0.334B 54.33
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.104B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00